Universal reference book for medicines
Product name: TAGERA (TAGERA)

Active substance: secnidazole

Type: Antiprotozoal preparation with antibacterial activity

Manufacturer: UNICHEM Laboratories (India)
Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..

Antimicrobial and antiprotozoal agent, synthetic derivative of nitroimidazole.

It is active against obligate anaerobic bacteria (sporo- and non-spore forming), pathogens of some protozoal infections: Trichomonas vaginalis, Giardia lamblia, Entamoeba histolytica.

Not active against aerobic bacteria.

Increases the sensitivity of tumors to radiation, causes sensitization to ethanol (disulfiram-like action).
Interacts with DNA, causes disruption of the spiral structure, rupture of filaments, suppression of the synthesis of nucleic acids and cell death.
Secnidazole has a high degree of absorption, bioavailability is 80%.
Metabolised in the liver. C max after a single oral intake of 2 g is achieved after 4 hours. It is excreted by the kidneys: within 72 hours - 16% of the accepted dose. Isolated with breast milk, penetrates the placental barrier.
Trichomonas urethritis and vaginitis, intestinal amebiasis, amebiasis of the liver, giardiasis.

For oral administration for adults, the dose is 2 g / day, for children - 30 mg / kg / day in one or more doses.
The course of treatment is from 1 to 5 days.
Often: dyspeptic symptoms (including nausea, pain in the stomach), metallic taste in the mouth, glossitis, stomatitis, moderate reversible leukopenia, urticaria.

Rarely: dizziness, impaired coordination, ataxia, paresthesia, polyneuropathy.

Organic diseases of the central nervous system, pathological changes in the pattern of peripheral blood (including in the anamnesis), pregnancy, lactation (breastfeeding), hypersensitivity to imidazole derivatives.

Seknidazole is contraindicated in pregnancy and lactation (breastfeeding).

Penetrates through the placental barrier.
Clinical data on safety of use in pregnancy are absent. In experimental studies, no teratogenic effect of secnidazole was detected.
Seknidazole is excreted in breast milk, so if it is necessary to use during lactation it is necessary to stop breastfeeding.

The application is possible according to the dosing regimen.

During the treatment period, you should avoid drinking alcohol.

When concomitant use of secnidazole with anticoagulants (coumarin or indanedione derivatives), the effect of the latter can be strengthened, therefore, prothrombin time should be monitored periodically and, if necessary, adjusted doses of anticoagulants.

With the simultaneous use of secnidazole with disulfiram, it is possible to develop paranoia and psychosis;
with ethanol - it is possible to develop effects similar to the action of disulfiram (abdominal cramps, nausea, vomiting, headache, sudden rush of blood to the face).
It is not recommended to combine with nondepolarizing muscle relaxants (vecuronium bromide).

With simultaneous reception with lithium preparations, secnidazole increases its concentration in plasma.

When combined with amoxicillin, Helicobacter pylori activity increases (amoxicillin suppresses the development of resistance).

[MSK] 01.04 in the RK is not registered.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y

Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!